CME Group (NASDAQ:CME) Releases Quarterly Earnings Results

CME Group (NASDAQ:CME) announced its quarterly earnings results on Wednesday. The financial services provider reported $2.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.91 by $0.08, FiscalAI reports. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.68 billion. CME Group had a net margin of 63.19% and a return on equity of 15.42%.

CME Group Stock Performance

CME Group stock opened at $237.41 on Wednesday. The firm has a market capitalization of $86.03 billion, a P/E ratio of 20.26, a PEG ratio of 3.05 and a beta of 0.25. The stock has a fifty day moving average price of $256.83 and a 200 day moving average price of $281.68. CME Group has a 52 week low of $218.31 and a 52 week high of $329.16. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13.

CME Group Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Tuesday, June 9th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. CME Group’s payout ratio is currently 44.37%.

Key CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: CME Group beat Q2 earnings and revenue estimates, showing continued strength in trading volume and core exchange activity. CME Group Inc. Reports Strong Financial Results for Q2 2026
• Positive Sentiment: The company highlighted strong operating performance, with second-quarter operating income of about $1.1 billion and continued high market participation. CME Group Q2 earnings beat, buoyed by second-highest trading volume
• Neutral Sentiment: Analyst coverage remains mixed, with recent price targets ranging from the mid-$200s to the low-$300s, suggesting expectations are still divided on how much upside remains. CME: Q2 Earnings Snapshot
• Negative Sentiment: The stock is still trading well below its recent moving averages, indicating investors remain cautious despite the earnings beat.

Insiders Place Their Bets

In other news, insider Hilda Harris Piell sold 5,753 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $304.63, for a total transaction of $1,752,536.39. Following the transaction, the insider directly owned 27,702 shares in the company, valued at $8,438,860.26. This represents a 17.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Terrence A. Duffy sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $298.51, for a total transaction of $10,447,850.00. Following the completion of the sale, the chief executive officer directly owned 55,630 shares in the company, valued at $16,606,111.30. This represents a 38.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CME Group

Large investors have recently bought and sold shares of the stock. Elkhorn Partners Limited Partnership acquired a new position in shares of CME Group in the 4th quarter valued at $27,000. Strive Asset Management LLC purchased a new position in shares of CME Group in the 3rd quarter worth $32,000. Acumen Wealth Advisors LLC acquired a new position in CME Group in the fourth quarter valued at $33,000. Kemnay Advisory Services Inc. acquired a new position in CME Group in the fourth quarter valued at $39,000. Finally, Uniplan Investment Counsel Inc. grew its position in CME Group by 281.6% during the fourth quarter. Uniplan Investment Counsel Inc. now owns 145 shares of the financial services provider’s stock valued at $40,000 after acquiring an additional 107 shares during the period. Hedge funds and other institutional investors own 87.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CME shares. UBS Group cut their price objective on CME Group from $310.00 to $260.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Wall Street Zen downgraded CME Group from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Keefe, Bruyette & Woods raised CME Group from a “market perform” rating to an “outperform” rating and set a $305.00 price target for the company in a report on Thursday, June 18th. Piper Sandler reduced their price objective on CME Group from $329.00 to $295.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 15th. Finally, Barclays decreased their price objective on CME Group from $316.00 to $270.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 9th. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.12.

CME Group Company Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.